Zepbound (tirzepatide) is a glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist that is FDA-approved along with increased physical activity and a reduced-calorie diet for chronic weight management in adults with a starting body mass index (BMI) of: 30 kg/m^2 or higher (obesity) or 27 kg/m^2 or higher (overweight) with at least one weight-related condition such as high cholesterol, high blood pressure (hypertension), type 2 diabetes, heart disease, or obstructive sleep apnea
From 2022 to 2023 alone, spending on GLP-1 RAs increased by 62% in the United States
Guidelines say that up to 2,000 micrograms a day is unlikely to cause problems and you shouldnt take more than that
If you want to lose weight, discuss your goals with your healthcare provider
Clients on GLP-1 protocols typically lose 10 to 20% or more of their body weight over 6 to 12 months of treatment
Kwon and Park 2015 reported that intra-articular AOD-9604 injections, especially when combined with hyaluronic acid, improved cartilage scores and reduced lameness in a rabbit collagenase-induced osteoarthritis model
